Back to Results

A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety extension period up to 52 weeks, in children and adolescents with type 2 diabetes mellitus.

Study category: Diabetes & Hormone Disorders

Is this Study for You?

Let's Get Started!

Details
Age

Child

Type of Study

Treatment

Location

Childrens Hospital Colorado

Principal Investigator
Petter Bjornstad,  MD

Petter Bjornstad, MD

Study ID

Protocol Number: 18-1223

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers